Condition
Chronic Renal Insufficiency
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
12 shownKidney Precision Medicine ProjectNCT04334707 · 2019-09-01
RECRUITINGStudy on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal InsufficiencyNCT07786571 · 2026-12-01
NOT_YET_RECRUITINGSocial Determinants in Chronic Disease in British ColumbiaNCT02203084 · 2014-09-01
COMPLETEDTreatment of Masked HypertensionNCT02142881 · 2014-06-01
COMPLETEDRenal Protection Using Sympathetic Denervation in Patients With Chronic Kidney DiseaseNCT02002585 · 2013-11-01
UNKNOWNInvestigations of the Optimum Serum Bicarbonate Level in Renal Disease.NCT01574157 · 2012-11-05
COMPLETEDRenal Transplantation and Raltegravir in HIV-Infected PatientsNCT01453192 · 2011-12-01
COMPLETEDA Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)NCT01407276 · 2011-08-08
COMPLETEDSafety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary ProcedureNCT01252810 · 2010-11-01
COMPLETEDEfficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal FailureNCT00716573 · 2008-09-16
COMPLETEDAn Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)NCT00095056 · 2004-10-01
COMPLETEDAfrican American Study of Kidney Disease and HypertensionNCT04364139 · 1995-02-01
COMPLETEDCommon interventions
AmlodipineDRUG1Antihypertensive medication intensificationOTHER1DorzagliatinDRUG1everolimusDRUG1GE-145DRUG1glipizideDRUG1Kidney BiopsyPROCEDURE1LinagliptinDRUG1MAP goal 102-107 mm HgOTHER1MAP goal less than or equal to 92 mm HgOTHER1MetoprololDRUG1MRIOTHER1OmarigliptinDRUG1PlaceboDRUG1Placebo to glipizideDRUG1Placebo to SitagliptinDRUG1RaltegravirDRUG1RamiprilDRUG1Renal denervationPROCEDURE1Retina ScanOTHER1sitagliptinDRUG1Social Determinants QuestionnaireOTHER1Sodium bicarbonateDRUG1Usual careOTHER1
Leading sponsors
Merck Sharp & Dohme LLC2ANRS, Emerging Infectious Diseases1Charles University, Czech Republic1GE Healthcare1Hospices Civils de Lyon1Icahn School of Medicine at Mount Sinai1National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1Sun Yat-sen University1University of British Columbia1University of Minnesota1VA Office of Research and Development1
Trial status mix
COMPLETED9
NOT_YET_RECRUITING1
RECRUITING1
UNKNOWN1
Phase mix
PHASE34
NA2
PHASE22
PHASE11
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.